Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-1724PMID 21880791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-host cell interactions in the bone disease of myeloma.

  2011cited by this paper
• Interleukin‐27 and interleukin‐23 modulate human plasmacell functions

  2011cited by this paper
• Sonoporation Delivery of Interleukin-27 Gene Therapy Efficiently Reduces Prostate Tumor Cell Growth In Vivo

  2011cited by this paper
• Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells.

  2010cited by this paper
• Cancer electrogene therapy with interleukin-12.

  2010cited by this paper
• Direct inhibition of human acute myeloid leukemia cell growth by IL-12.

  2010cited by this paper
• Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members.

  2010cited by this paper
• IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors

  2010cited by this paper
• IFN-β Inhibits Dendritic Cell Migration through STAT-1–Mediated Transcriptional Suppression of CCR7 and Matrix Metalloproteinase 9

  2010cited by this paper
• Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

  2010cited by this paper
• Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27

  2010cited by this paper
• A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.

  2010cited by this paper
• Pathogenesis of myeloma bone disease

  2009cited by this paper
• Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

  2009cited by this paper
• IL-17 and Th17 Cells.

  2009cited by this paper
• Antiproliferative Activity of IL-27 on Melanoma1

  2008cited by this paper
• Antiproliferative Activity of IL-27 on Melanoma

  2008cited by this paper
• IL-23 Induces Receptor Activator of NF-κB Ligand Expression on CD4+ T Cells and Promotes Osteoclastogenesis in an Autoimmune Arthritis Model1

  2008cited by this paper
• IL-23 Inhibits Osteoclastogenesis Indirectly through Lymphocytes and Is Required for the Maintenance of Bone Mass in Mice1

  2008cited by this paper
• Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

  2008cited by this paper
• Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions.

  2007cited by this paper
• Swords into plowshares: IL-23 repurposes tumor immune surveillance.

  2007cited by this paper
• Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation

  2007cited by this paper
• Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma

  2007cited by this paper
• IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats

  2007cited by this paper
• Essential Roles of c-Rel in TLR-Induced IL-23 p19 Gene Expression in Dendritic Cells1

  2007cited by this paper
• Endogenous IL-12 triggers an antiangiogenic program in melanoma cells

  2007cited by this paper
• Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-121

  2007cited by this paper
• Differential Effects of IL-27 on Human B Cell Subsets1

  2006cited by this paper
• Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.

  2006cited by this paper
• IL-23 promotes tumour incidence and growth

  2006cited by this paper
• Dysfunctional T regulatory cells in multiple myeloma.

  2006cited by this paper
• Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.

  2006cited by this paper
• Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant1

  2006cited by this paper
• Bone marrow angiogenesis in multiple myeloma

  2006cited by this paper
• Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

  2006cited by this paper
• Immune enhancement and anti-tumour activity of IL-23

  2006cited by this paper
• Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma.

  2006cited by this paper
• Antiangiogenic and Antitumor Activities of IL-271

  2006cited by this paper
• Review: Novel Nonviral Delivery Approaches for Interleukin-12 Protein and Gene Systems: Curbing Toxicity and Enhancing Adjuvant Activity

  2006cited by this paper
• Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.

  2006cited by this paper
• Langowski JL, Zhang XQ, Wu LL et al.IL-23 promotes tumour incidence and growth. Nature 442:461-465

  2006cited by this paper
• Differential effects of IL-27 on human B cell subsets

  2006influential reference
• IL-27Antiangiogenic and Antitumor Activities of

  2006cited by this paper
• Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

  2006cited by this paper
• New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

  2005cited by this paper
• Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

  2005cited by this paper
• miR-15 and miR-16 induce apoptosis by targeting BCL2.

  2005cited by this paper
• Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

  2004cited by this paper
• Pathogenesis of myeloma bone disease.

  2004cited by this paper
• Potent Antitumor Activity of Interleukin-27

  2004cited by this paper
• WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27

  2004cited by this paper
• The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies.

  2004cited by this paper
• The IL-12Rβ2 gene functions as a tumor suppressor in human B cell malignancies

  2004cited by this paper
• Drug therapy: Multiple myeloma

  2004cited by this paper
• Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

  2004cited by this paper
• New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

  2004cited by this paper
• Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.

  2003cited by this paper
• Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells.

  2003cited by this paper
• Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects

  2003cited by this paper
• The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses.

  2003cited by this paper
• Antitumor and Antimetastatic Activity of IL-231

  2003cited by this paper
• Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.

  2002cited by this paper
• A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1

  2002cited by this paper
• The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression.

  2002cited by this paper
• Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature

  2002cited by this paper
• Transcription of the Interferon γ (IFN-γ)-inducible Chemokine Mig in IFN-γ-deficient Mice*

  2001cited by this paper
• Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma

  2001cited by this paper
• Transcription of the interferon gamma (IFN-gamma )-inducible chemokine Mig in IFN-gamma-deficient mice.

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Multiple myeloma

  2001cited by this paper
• Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

  2000cited by this paper
• Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

  2000cited by this paper
• Prognostic value of bone marrow angiogenesis in multiple myeloma.

  2000cited by this paper
• Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice.

  1999cited by this paper
• Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

  1999cited by this paper
• Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

  1999cited by this paper
• Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

  1999cited by this paper
• Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

  1999cited by this paper
• Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12

  1998cited by this paper
• Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells.

  1997cited by this paper
• Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

  1997cited by this paper
• Multiple myeloma.

  1948cited by this paper
• Reprints Available Directly from the Publisher Photocopying Permitted by License Only Proteolytic Activity of Human Lymphoid Tumor Cells. Correlation with Tumor Progression

  year unknowncited by this paper

• Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia

  2026cites this paper
• Angiogenesis in Multiple Myeloma: 25 Years of Research in This Field

  2025cites this paper
• The Impact and Mechanism of Action of Peptostreptococcus anaerobius on Chemotherapy Resistance in Human Colorectal Cancer

  2024cites this paper
• The IL-23R and Its Genetic Variants: A Hitherto Unforeseen Bridge Between the Immune System and Cancer Development

  2024cites this paper
• Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance

  2022cites this paper
• IL-23 and the Tumor Microenvironment.

  2021cites this paper
• PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients

  2021cites this paper
• Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role

  2020cites this paper
• Association of IL-27 rs153109 and rs17855750 Polymorphisms with Risk and Response to Therapy in Acute Lymphoblastic Leukemia

  2018cites this paper
• Aberrant expression of interleukin-23-regulated miRNAs in T cells from patients with ankylosing spondylitis

  2018cites this paper
• Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence

  2018cites this paper
• A review on interleukins: The key manipulators in rheumatoid arthritis

  2017cites this paper
• [Potential relationship and clinical significance of miRNAs and Th17 related cytokines in patients with multiple myeloma].

  2015cites this paper
• Potential relationship and clinical significance of miRNAs and Th17 cytokines in patients with multiple myeloma.

  2014cites this paper
• Interleukin-27: Regulation of Immune Responses and Disease Development by a Pleiotropic Cytokine with Pro- and Anti-inflammatory Properties

  2014cites this paper
• A Polyglutamic Acid Motif Confers IL-27 Hydroxyapatite and Bone-Binding Properties

  2013cites this paper
• Multiple myeloma in a patient under ustekinumab--are they related?

  2013cites this paper
• This information is current as PropertiesHydroxyapatite and Bone-Binding A Polyglutamic Acid Motif Confers IL-27

  2013cites this paper
• Antiangiogenic therapeutic approaches in multiple myeloma.

  2012cites this paper
• Dysregulated ERK signal pathway and immune profiles in Fragile X Syndrome

  2012cites this paper